Shots:

• The company reported that the COVID-19 vaccine is safe- well-tolerated & immunogenic in the P-I/II study & plans to initiate P-III clinical trial in ~30000 volunteers upon receiving necessary approvals
• The P-II study of ZyCoV-D had been conducted in ~1000 healthy adult volunteers as part of the adaptive P-I/II dose-escalation study
• The trial has been reviewed by an independent DSMB & reports have been submitted to CDSCO regularly for the update on safety outcome

 ­ Ref: Zydus Cadila | Image: eHealth Magazine